Nika Pharmaceuticals Q2 FY26 net loss widens to $19,694
NIKA•Q2 net loss widens as expenses edge up
Nika Pharmaceuticals posted a net loss of USD 19,694 for the quarter ended June 30, 2026, widening from USD 18,381 a year earlier.
- General and administrative expenses edged up to USD 14,848 from USD 14,300.
- Professional fees rose to USD 4,846 from USD 4,081.
- Net cash used in operating activities narrowed to USD 20,957 for the six months ended June 30, 2026, versus USD 31,467 a year earlier.
- Related-party loan proceeds fell to USD 22,000 from USD 45,000.
- The company reported no revenue and reliance on non-interest-bearing loans.
- Management cited a timing shift in prepaid-expense amortization, adding about USD 7,820 to second-quarter expenses that otherwise would have been recorded in Q1.
